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Glenn F. Carlson · Conrad K. P. Tou · Shamik Parikh · Bruce K. Birmingham · Kathleen Butler
ABSTRACT
Introduction: Dapagliflozin is a first-in-class 
sodium-glucose transporter 2 (SGLT2) inhibitor 
under investigation for the treatment of type 
2 diabetes mellitus. A thorough QTc study 
was conducted, according to International 
Conference on Harmonization E14 guidelines, 
to characterize the effect of dapagliflozin on 
cardiac repolarization. Methods: The present 
study was a double-blind, four-period, placebo-
controlled crossover study at a single-center 
inpatient clinical pharmacology unit. The 
study enrolled 50 healthy men who were 
randomized to receive sequences of single 
doses of dapagliflozin 150 mg, dapagliflozin 
20 mg, moxifloxacin 400 mg, and placebo. 
The sequences were randomized based on 
the Williams design for a cross-over study to 
reduce the “carryover” effects from drug-to-
drug even with sufficient washout periods. 
Digital 12-lead electrocardiograms were 
recorded at nine time points over 24 hours 
in each period. QT intervals were corrected 
for heart rate using a study-specific correction 
factor (QTcX) and Fridericia’s formula. Results: 
For dapagliflozin, the upper bound of the
one-sided 95% confidence interval (CI) for 
time-matched, placebo-subtracted, baseline 
adjusted QTc intervals (∆∆QTc) was <10 ms. 
∆∆QTc was independent of dapagliflozin 
concentrations. No QTc thresholds >450 ms 
or QTc increases >30 ms were observed. 
Moxifloxacin increased the mean QTcX 
interval by 7.7 ms (lower bound 90% CI, 
6.2 ms) over 1-4 hours after dosing, confirming 
assay sensitivity. Conclusion: Dapagliflozin, 
at supratherapeutic doses, does not have a 
clinically significant effect on the QT interval 
in healthy subjects.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a worldwide 
epidemic, with approximately 285 million 
patients at present and a projected rise 
to 439 million by 2030.1 This progressive 
disease typically requires chronic lifestyle 
and pharmacologic management to maintain 
effective glycemic control. Given the potential 
for extensive exposure and continued therapy, 
investigational drugs for T2DM demand 
rigorous evaluation for potential long-term 
safety concerns, including potential effects 
on cardiac repolarization. Delayed ventricular 
repolarization, as measured by a prolonged QT 
interval, has been associated with an increased 
risk of arrhythmias, including torsades de 
pointes.2
Dapagliflozin is a first-in-class oral, once-
daily, potent, and highly selective sodium 
glucose cotransporter 2 (SGLT2) inhibitor 
being developed for the treatment of T2DM.3,4 
Treatment with dapagliflozin promotes urinary 
glucose excretion by preventing up to 50% of 
the filtered glucose from being reabsorbed.5,6 
Thus, by inhibiting renal glucose reabsorption, 
SGLT2 inhibition provides a mechanism for 
improving glycemic control in patients with 
T2DM that is independent of insulin secretion 
or insulin action.
The pharmacokinetics of dapagliflozin 
have been assessed in both healthy volunteers 
and patients with T2DM.5,6 Dapagliflozin is 
rapidly absorbed after oral administration, 
has a terminal elimination half-life (t1/2) of 
approximately 16 hours, and is primarily 
metabolized by UGT1A9 to an inactive 
O-glucuronide that is eliminated renally. 
Results from placebo-controlled clinical trials 
have demonstrated that dapagliflozin improves 
glycemic control in patients with T2DM and is 
well tolerated.6-8
The potential effect of dapagliflozin on 
ventricular repolarization (QT/QTc) was 
previously investigated in nonclinical assays. 
Dapagliflozin minimally inhibited the human 
cardiac delayed rectifier potassium current, coded 
by the human ether-a-go-go-related gene, by
3.7% at 4 μg/mL, a concentration approximately 
800 times greater than the maximum observed 
plasma drug concentration (Cmax) of a 10 mg dose 
in humans. The 10 mg dose has been the largest 
dose assessed in phase 3 dapagliflozin clinical 
trials.9,10 Likewise, no increase in QTc was observed 
in dogs given a dose of 120 mg/kg per day
(Bristol-Myers Squibb, unpublished results).
While the preclinical results suggest there is
little risk for QT interval prolongation in 
humans, concerns about the cardiovascular 
risk of antidiabetic drugs have recently been 
raised.11,12 Current recommendations require
that all nonarrhythmic compounds undergo 
clinical evaluation of QT/QTc interval 
prolongation by means of a thorough QT 
(TQT) study.2 The purpose of this TQT 
study was to provide an assessment of the 
potential for a single dose of dapagliflozin to 
prolong ventricular repolarization by testing
the hypothesis that dapagliflozin does not prolong 
the QTc interval while ensuring the rigorousness 
of the conclusion by assessing the ability of 
moxifloxacin to increase the QTc interval.
METHODS
This study was designed and monitored in 
accordance with ethical principles of Good 
Clinical Practice as defined by the International 
Conference on Harmonisation and the 
Declaration of Helsinki. An Institutional Review 
Board (Chesapeake Research Review, Inc, 
Columbia, MD, USA) approved the protocol 
before trial commencement, and all subjects 
gave written, informed consent.Diabetes Ther (2011)  2(3):123-132. 125
Subjects
Inclusion criteria were: healthy men between the 
ages of 18 and 45 years, with a body mass index 
between 20 and 28 kg/m2. Exclusion criteria 
were: an abnormal electrocardiogram (ECG); 
history of arrhythmia; QT interval corrected 
for heart rate using Fridericia’s formula (QTcF) 
>450 ms; use of chronic prescription medication; 
history or presence of neurologic, hematologic, 
psychiatric, gastrointestinal, hepatic, or renal 
disease; consumption of caffeine-containing 
products within 24 hours of dosing; or history 
of hypoglycemia. Subjects were to refrain from 
alcohol consumption during the entire study, 
strenuous exercise 48 hours before study day 1 of 
each period, and over-the-counter preparations, 
including herbal remedies.
Study Design
This study, conducted at PAREXEL Clinical 
Research Unit (Baltimore, MD, USA), was a 
double-blind, double-dummy, randomized, four-
period crossover study with an active control. 
There were four single-dose treatment periods, 
with a 7-10-day washout period between each 
dose. Treatment sequences were randomized 
based on the Williams design for a cross-over 
study to reduce the potential “carryover” effects 
from drug to drug even with sufficient washout 
periods.
Subjects were screened within 21 days of 
randomization. Each subject received the 
following four treatments, administered in 
the order prescribed by the sequence to which 
the subject had been randomly assigned: 
Treatment A, dapagliflozin 150 mg; Treatment 
B, dapagliflozin 20 mg; Treatment C, over 
encapsulated moxifloxacin 400 mg; and 
Treatment D, placebo. Subjects underwent a 
10-hour fast before dosing, and no food was 
allowed until 4 hours afterward. Each dose was 
administered with 240 mL of water.
Safety
Subjects were confined to the clinical research 
unit for 72 hours after dosing. Vital signs, 
12-lead safety ECG, physical examinations, and 
safety laboratory analyses involving routine 
hematology, serum chemistry, and urinalysis 
were obtained throughout the study and at a 
follow-up examination 5-7 days after the last 
treatment period. All adverse events (AEs) were 
evaluated by the investigator and characterized 
with respect to intensity, duration, relationship 
to study drug, and outcome.
Pharmacodynamic Measurements
Recording of Digital Electrocardiogram
Twelve-lead continuous digital ECG (dECG) 
recordings were obtained using a Schiller 
Cardiovit CS-200 recorder (Schiller AG, 
Baar, Switzerland) and analyzed by EClysis®
(ECG Analysis, AstraZeneca proprietary tool, 
Wilmington, DE, USA) an automated reading 
method for dECG intervals with manual 
adjudication.13 Recordings were taken for 
10 minutes before dosing and then resumed 
15 minutes after dosing until 3 hours after 
dosing. From the 0-3 hour recording, 5 minute 
recordings were selected at 0.5, 1, 2, and 3 hours. 
Thereafter, 5 minute recordings were taken at
4, 6, 8, 12, and 24 hours after dosing. All dECG 
measurements were obtained just before blood 
draws for pharmacokinetic assessment.
Determination of Digital Electrocardiogram 
Parameters
The following dECG variables were reported: RR 
interval, PR interval, QRS interval, QTtang interval, 
and QT interval corrected for heart rate using a 126 Diabetes Ther (2011)  2(3):123-132.
study-specific factor (QTcX), QTcF, and Bazett’s 
correction (QTcB). Ten-second dECGs were 
extracted every 30 seconds from the predefined 
5-minute continuous recording. The extracted 
data were averaged to arrive at a mean for each 
time point. The QTtang interval is the QT interval 
measured by Eclysis® from the beginning of the 
Q wave to the intercept between the isoelectric 
line and the regression line, derived on the 
T-wave downstroke for values between 80% and 
20% of the T-top amplitude.
The primary variable was QTcX, which was 
derived from the dECG using a study-specific 
correction factor. QTcX was calculated by the 
equation QTcX=QTtang/RRb, with the QTtang 
interval expressed in milliseconds and the RR 
interval in seconds.14 The correction factor b was 
estimated using a linear mixed-effect model with 
volunteer as a random effect. The dependency 
between the QTtang interval and the RR interval 
was assumed to be described by:
log (QTtang) = a  +  b  x  log (RR),
where  a was a random subject effect. The 
estimate was based on all predose measurements 
from all periods. The QTc interval calculated by 
QTcF used b=1/3 and by QTcB used b=1/2.
Pharmacokinetic Measurements
For dapagliflozin and its metabolite 
(BMS-801576), the following single-dose 
pharmacokinetic parameters were derived from 
the plasma concentration versus time data: area 
under the plasma concentration versus time 
curve from time zero to infinity (AUC), Cmax, 
time to Cmax (tmax), and t1/2. AUC was determined 
using the linear trapezoidal rule, while Cmax and 
tmax were determined by visual inspection of 
the plasma concentration versus time curve. The 
t1/2 was calculated as 0.693/λz, where λz was the 
terminal elimination rate constant derived from 
the log-linear regression of the terminal portion 
of the plasma concentration versus time curve.
Bioanalytical Methods
Assays for plasma concentrations of 
dapagliflozin and BMS-801576 were performed 
by ATLANBIO (Saint-Nazarine, France) 
using liquid chromatography tandem mass 
spectrometry detection. The between-run 
variability and within-run variability for the 
analytical quality controls of dapagliflozin 
were 0.0% and ≤8.7%, respectively, for the 
coefficient of variation, with deviations from 
the nominal concentrations of ±3.6%. The 
respective numbers for BMS-801576 were ≤3.6% 
and ≤9.5%, and ±7.3%. For both dapagliflozin 
and BMS-801576, the assay range representing 
the lower and upper limits of quantification in 
plasma was 1.0-500 ng/mL.
Statistical Analysis
The primary comparison was a test of 
noninferiority of dapagliflozin 150 mg compared 
with placebo for the mean, time-matched 
differences in change from baseline in QTcX. All 
one-sided 95% confidence intervals (CIs) needed 
to be <10 ms at each of the nine time points 
examined. Assuming a drug effect of 2 ms and 
a standard deviation of within-subject changes 
from baseline (ΔQTc) of 8.5 ms, 36 subjects were 
required for 90% power for each of the nine 
time points to be <10 ms. The QTcX analysis set 
consisted of all volunteers who had data available 
for all four periods, including the baseline.
Three different contrasts (dapagliflozin 
150 mg vs. placebo; dapagliflozin 20 mg vs. 
placebo; and moxifloxacin 400 mg vs. placebo) 
were estimated in the same model. The QTcX at 
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was analyzed by repeated measures analysis of 
covariance. The treatment effect of dapagliflozin 
with its upper bound of a two-sided 90% CI was 
evaluated against the margin of 10 ms at each of 
the nine time points.
To test for assay sensitivity, a linear contrast 
comparing moxifloxacin versus placebo from 
the primary analysis model on mean QTcX over 
1, 2, 3, and 4 hours after dosing was analyzed.
A two-sided 90% CI was constructed for this 
mean time period. The lower bound of the 
two-sided 90% CI was evaluated against the 
threshold of 5 ms.
The QT versus dapagliflozin concentration 
analysis used a linear mixed-effect model. The 
null hypothesis of zero-slope was tested with 
a two-sided t-test at the 5% significance level.
If the slope was significant, the predicted 
ΔΔQTcX and its corresponding upper 90%
two-sided CI bound were to be computed at the 
Cmax of the therapeutic dose of dapagliflozin.
RESULTS
A total of 50 healthy men were randomized and 
received study drug. Enrolled subjects ranged in 
age from 19 to 44 years (mean, 32 years) and 
in BMI from 20 to 28 kg/m2 (mean 25 kg/m2). 
They were classified by race as white, 14 (28%); 
black, 34 (68%); Asian, 1 (2%), and American 
Indian or Alaska Native, 1 (2%). Thirteen 
subjects discontinued from the study. Of those 
13 subjects, six were unwilling to continue the 
protocol, and three were removed for severe 
noncompliance with the protocol. One subject 
was withdrawn for AEs (pharyngeal pain, 
myalgias, and headache). Two subjects were 
withdrawn at the request of the investigator, 
one for pruritus and urticaria, and the other 
because he developed a resting heart rate
<50 beats/min before dosing in one period. 
The final subject withdrawn from the study 
developed hypertension; he later admitted 
to stopping hypertension medications before 
randomization, and thus was ineligible for 
inclusion in the study.
QTc Interval
The value of the study-specific correction factor 
(b) for QTcX was 0.209. The placebo-subtracted, 
baseline-adjusted mean QTcX for dapagliflozin 
(20 mg and 150 mg) was <5 ms at each time 
point, and all upper bounds of the two-sided 
90% CI for the contrasts were <10 ms (Figure 1). 
The maximum placebo-subtracted, baseline-
adjusted mean effect of dapagliflozin 150 mg 
for QTcX was 1.2 ms at 3 hours after dosing, 
and the upper bound of the CI was 3.4 ms. For 
dapagliflozin 20 mg, the maximum placebo-
corrected, baseline-adjusted mean effect for 
QTcX was 2.3 ms at 8 hours after dosing
(90% CI, 0.0 to 4.6) (Table 1).
Similar findings were observed using QTcF. 
The maximum placebo-subtracted, baseline-
adjusted mean effect for QTcF was 2.8 ms
(90% CI, 0.6 to 5.1) and 1.6 ms (90% CI, −0.7 
to 3.9) for the 20 mg and 150 mg dapagliflozin 
doses, respectively (Table 1). The findings for 
QTcB were consistent with those for QTcF.
Figure 1. Placebo-subtracted (time-matched), baseline-
adjusted least-squares (LS) mean difference in QTcX 
interval versus sample time.128 Diabetes Ther (2011)  2(3):123-132.
For moxifloxacin, with the exception of 
the contrast at 0.5 and 12 hours after dosing, 
all point estimates for the contrasts between 
moxifloxacin 400 mg and placebo for QTcX 
were >5 ms, and the lower bounds of the
90% CI were >5 ms at 3 and 4 hours. The 
maximum placebo-corrected, baseline-adjusted 
mean effect of moxifloxacin 400 mg for QTcX was
9.7 ms at 4 hours after dosing, and the lower 
bound of the two-sided 90% CI was 7.5 ms 
(Table 1).
Assay sensitivity was demonstrated by 
comparing the moxifloxacin and placebo 
treatments using the primary analysis model for 
QTcX averaged over the 1-, 2-, 3-, and 4-hour 
postdose time points. The average 1-4 hour 
effect of moxifloxacin on the placebo-corrected, 
baseline-adjusted QTcX was 7.7 ms, with a lower 
bound of the 90% CI of 6.2 ms.
QTc Interval Increase From Baseline and 
Absolute QTc Interval Prolongation
Figure 2 presents a plot of the shift from 
baseline to the maximum observed QTcX 
interval by treatment.There was no increase 
from baseline >30 ms for QTcX over the 
24-hour period following dapagliflozin or 
placebo administration. Only one subject had 
an increase from baseline >30 ms for QTcX after 
administration of moxifloxacin 400 mg (3-hour 
postdose time point).
Two subjects had an increase from baseline 
of 30 ms for QTcF over the 24 hours of 
treatment with moxifloxacin. These values, 
30.2 and 31.1 ms, occurred at 4 and 3 hours 
after dosing, respectively. No subject had
an increase from baseline for QTcF >30 ms
for any dose of dapagliflozin. No subjects
had a QTcX or QTcF value >450 ms during
the study.
Concentration-QT Relationship
Mean individual QTcX intervals versus 
dapagliflozin (20 mg and 150 mg) plasma 
concentration are presented in Figure 3. There 
was no apparent concentration-dependent effect 
of dapagliflozin on QTcX. The estimated slope 
was –0.29 ms/μg per mL, and the test of the null 
hypothesis of zero slopes was not statistically 
significant (P=0.51).
Table 1. Maximum placebo-subtracted, baseline-adjusted 
mean QTcX and QTcF intervals for dapagliflozin and 
moxifloxacin.
  Maximum placebo-  Maximum placebo- 
  subtracted,  subtracted, 
  baseline-adjusted  baseline-adjusted 
  mean QTcX,  mean QTcF, 
  ms (90% CI)  ms (90% CI)
Dapagliflozin 
150 mg  1.2 (−1.0 to 3.4)  1.6 (−0.7 to 3.9)
Dapagliflozin 
20 mg  2.3 (0.0 to 4.6)  2.8 (0.6 to 5.1)
Moxifloxacin  9.7 (7.5 to 11.9)  11.5 (9.2 to 13.7)
CI=confidence interval; QTcF=QT interval corrected 
using Fridericia’s formula; QTcX=QT interval corrected 
for heart rate using a study-specific factor.
Figure 2. Shift from baseline to the maximum observed 
QTcX interval by treatment.Diabetes Ther (2011)  2(3):123-132. 129
Effect on RR, QRS, and PR Intervals
There was little effect of dapagliflozin on heart 
rate. The mean change from baseline in the 
RR interval at each time point ranged from 
14.8 to –138.4 ms for dapagliflozin 150 mg, 
2.9 to –135.9 ms for dapagliflozin 20 mg, 8.4 to 
Figure 3. Mean individual QTcX intervals versus 
dapagliflozin (150 mg and 20 mg) plasma concentration.
Table 2. Effect on RR, QRS and PR intervals.
  Range of the mean change  Range of the mean change  Range of the mean change 
  from baseline in the  from baseline in the  from baseline in the 
  RR interval (ms) at  QRS interval (ms) at  PR interval (ms) at 
  each time point  each time point  each time point
Dapagliflozin 150 mg   14.8 to −138.4  −0.2 to −1.5  0.2 to −8.1
Dapagliflozin 20 mg  2.9 to −135.9  0.0 to −0.9  −0.2 to −8.7
Moxifloxacin  8.4 to −127.8  0.0 to −1.4  −0.2 to −8.2
Placebo  20.4 to −128.1  0.0 to −1.5  1.1 to −7.8
Table 3. Pharmacokinetic parameters for dapagliflozin and BMS-801576.
  20 mg dose  150 mg dose
  Dapagliflozin  Inactive metabolite  Dapagliflozin  Inactive metabolite
Parameter  (n=41)  BMS-801576  (n=44)  BMS-801576
Cmax (ng/mL)  250.7 (26.6)  369.7 (34.7)  1981.0 (37.8)  2863.2 (38.5)
AUC (ng/h/mL)  1063.7 (24.3)  1950.3 (26.7)  8753.6 (24.4)  16,002 (32.2)
tmax (h)*  1 (0.5-3)  2 (1-4)  1 (0.5-4)  2 (0.5-6)
t1/2 (h)  13.8 (55.2)  12.4 (50.8)  14.8 (55.7)  14 (48.5)
*Data for tmax are median (range); all others are geometric mean (coefficient of variation, %).
AUC=area under the plasma concentration-time curve from 0 to infinity; Cmax=maximum plasma drug concentration; 
t1/2=half-life; tmax=time to reach Cmax.
–127.8 ms for moxifloxacin 400 mg, and 20.4 to 
–128.1 ms for placebo. Results were similar for 
QRS and PR intervals regardless of treatment 
(Table 2). 
Pharmacokinetics
Pharmacokinetic parameters of dapagliflozin 
and BMS-801576 are presented in Table 3. 
Dapagliflozin was rapidly absorbed after oral 
administration, with a median time to Cmax of 
1 hour for both the 20 mg and 150 mg doses. 
The geometric Cmax and AUC values appeared 
to increase in a dose-proportional manner. 
The geometric mean t1/2 was 14.8 hours after 
dapagliflozin 150 mg administration and
13.8 hours after 20 mg administration. Maximum 
plasma concentrations of BMS-801576 were 
reached at a median time of 2 hours after 
dapagliflozin administration.130 Diabetes Ther (2011)  2(3):123-132.
Safety
There were no deaths during this study. One 
subject experienced a serious AE, a transient 
ischemic attack, approximately 8 days after 
receiving moxifloxacin in the final period. This 
AE was not considered by the investigator to be 
drug related.
Nineteen subjects had AEs during the study, 
including nine subjects after dapagliflozin 
administration. Headache was the only AE 
reported by more than one subject after 
dapagliflozin administration, occurring in three 
and two subjects who received the 150 mg and 
20 mg dose, respectively. Other AEs reported after 
administration of dapagliflozin 150 mg were 
conjunctivitis, diarrhea, myalgia, pharyngeal 
pain, and tinea versicolor; those after the 20 mg 
administration were nausea, palpitations, 
paresthesia, pruritus, and urticaria. All AEs 
were of mild intensity. Overall, 11.4%, 12.2%, 
12.2%, and 10.9% of subjects experienced an 
AE after administration of dapagliflozin 150 mg, 
dapagliflozin 20 mg, moxifloxacin 400 mg, and 
placebo, respectively.
DISCUSSION
The assessment of a drug to delay cardiac 
repolarization, as assessed by the QT/QTc 
interval, is now required for compounds in 
development.19 The objective of this study 
was to provide a rigorous assessment of the 
potential for dapagliflozin to prolong ventricular 
repolarization in human subjects at both 
presumed therapeutic and supratherapeutic 
doses. The primary endpoint compared the 
change in QTc interval from predose baseline 
values between active and placebo treatment.
The mean QTc intervals were not prolonged 
using a study-specific correction method (QTcX) 
or the standard heart rate correction method 
(Fridericia’s). With both methods, all upper 
bounds of the 90% CI for the difference in mean 
QTc interval between either dose of dapagliflozin 
and placebo were <10 ms. Therefore, either 
correction method resulted in a negative TQT 
study, defined as one in which the upper bound 
of the 95% one-sided CI for the largest time-
matched mean effect of the drug on the QTc 
interval excludes 10 ms. This definition is meant 
to imply that the mean effect of a study drug on 
the QTc interval is not >5 ms.15 Both doses of 
dapagliflozin, using either heart rate correction 
method, met this requirement, as the largest 
placebo-subtracted, baseline-adjusted mean QTc 
interval for any dose or method of heart rate 
correction was only 2.8 ms. No subject treated 
with dapagliflozin had outlier values, namely 
an increase in QTcX or QTcF from baseline 
>30 ms or a QTcX or QTcF value >450 ms. The 
lack of outliers provides further confidence that 
dapagliflozin does not prolong the QTc interval.
In addition to the standard analysis of 
a TQT study, this study also incorporated 
concentration-QT modeling.15 The QTc 
versus concentration plot for dapagliflozin 
was essentially flat, with a slope that was not 
significantly different from zero. As ΔΔQTcX 
was independent of dapagliflozin plasma 
concentration, no further concentration/
QT modeling was explored. However, the 
concentration-QT modeling was consistent with 
the earlier phase 1 studies, which incorporated 
greater doses of dapagliflozin than the 
supratherapeutic dose used in this study. As some 
have noted,16 if the concentration-QT modeling 
in early clinical studies suggests that the TQT 
will be negative, the standard therapeutic dose 
can be omitted, allowing one arm of the study to 
be dropped. Although the anticipated maximum 
therapeutic dose was included, it could have 
been omitted without altering the conclusions 
on cardiac repolarization by dapagliflozin.Diabetes Ther (2011)  2(3):123-132. 131
The sensitivity of the assay to detect small 
increases in QTc interval was established with 
the active control, moxifloxacin. Although assay 
sensitivity was originally defined as a significant 
increase in QTc interval by the positive control 
that was consistent with its known effect on 
the QT interval,2 more recent requirements 
have proposed a prospective, more quantitative 
assessment that takes into account what is 
known about the response and time course of 
the positive control.15,17 For moxifloxacin, the 
lower bound of the 90% CI for one time point 
for ΔΔQTcX should be >5 ms. The time course 
for the QTc effect of moxifloxacin is known, 
and the peak effect occurs around the time of 
Cmax (ie, no hysteresis).18 Because moxifloxacin 
pharmacokinetic samples were not analyzed 
in this study, an average approach for Cmax was 
chosen because the mean tmax was unknown. It 
was prospectively decided to average the ΔΔQTcX 
for moxifloxacin over the 1-4-hour time points 
that encompass the tmax range for moxifloxacin. 
The ΔΔQTcX for the 1-4-hour average was 7.7 ms, 
with a lower bound of the 90% CI of 6.2 ms. 
The maximum baseline-adjusted, placebo-
subtracted QTcX for moxifloxacin was 9.7 ms, 
and the shape of the ΔΔQTcX versus time curve 
for moxifloxacin was consistent with previously 
published data.18 Therefore, assay sensitivity 
was confirmed in a rigorous way, validating the 
interpretability of the results for dapagliflozin.
Although the discontinuation rate of 
subjects in this study was greater than expected, 
it did not impact the results. A four-period 
crossover trial with a relatively long washout 
contributed to the dropout rate, as half of the 
discontinued subjects were dropouts and three 
additional subjects failed to comply with the 
protocol requirements. Both the dapagliflozin 
pharmacokinetic parameters and safety profile 
are consistent with previous results in healthy 
volunteers.5 The supratherapeutic dose of 
dapagliflozin appeared to be well tolerated. The 
percentage of subjects who experienced an AE 
was similar across the four groups, and all AEs 
were mild.
The inclusion of only healthy subjects is 
a limitation of this study. The typical TQT 
study is conducted in healthy volunteers, 
hence the results may not equate to potential 
proarrhythmic liabilities when a drug is used 
chronically in a high-risk cardiovascular 
population. This is pointed out in ICH-E14, as 
the TQT study is not intended to identify drugs 
as being proarrhythmic.19
CONCLUSION
Dapagliflozin at doses up to 150 mg was not 
associated with QT interval prolongation in 
healthy male subjects. There were no QTc 
thresholds above 450 ms or QTc interval increases 
>30 ms, and the QTc interval changes were 
independent of dapagliflozin concentrations. 
Based on these data, dapagliflozin at the 
proposed therapeutic dose of 10 mg/day is not 
expected to affect cardiac repolarization in 
patients with diabetes.
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